Activatable theranostic nanoprobes for Fluorescence/MR imaging and microenvironment remodeling of early cartilage degeneration

Osteoarthritis (OA) is a degenerative joint disease of the knee joint, suffering from the limited therapeutic effect and serious side effects. Unfortunately, there are currently rarely available materials to fundamentally delay and monitor OA progression. The OA microenvironment, including excessive inflammation, matrix metalloproteinases (MMPs), oxidative stress, and reactive oxygen species (ROS), play a crucial role in the pathogenesis of OA. Utilizing and remodeling OA microenvironment may be an effective strategy for the diagnosis and treatment of OA. This work developed an intelligent responsive nanoprobe, Gd-HMPB@SMT@MMP (GHPSM) by encapsulating S-methylisothiourea (SMT) loaded mesoporous Prussian Blue (Gd-HMPB) with Tetramethyl Rhodamine (TAMRA) labeled MMP-13 peptide (MMP-13-TAMRA) for this aim. GHPSM displayed enhanced accumulation in OA cartilage site due to the decrease in the content of negatively charged aminoglycans (GAGs) in early degenerative articular cartilage and activated fluorescence signal as well as SMT controlled release due to the cleavage of MMP-13-TAMRA from GHPSM by overexpressed MMP-13 matrix protease in OA microenvironment. Furthermore, integrating the function of SMT and PB nanozyme, GHPSM reshaped the OA microenvironment by reducing the release of ROS and inflammatory factors (TNF-α, IL-6, iNOS), increasing the expression of intermediate structural proteins (COL2 and Aggrescan), thereby reducing cartilage degradation and chondrocyte apoptosis, ultimately delaying the development of OA. The progressions of early OA disease after different treatments were successfully tracked based on fluorescence/MR imaging with X-ray imaging of knee joint for comparation. These findings highlight the potentials of GHPSM in monitoring the status of cartilage in real-time and delay OA progression by reshaping the OA microenvironment, providing novel ideas for future research in OA diagnosis and treatment.